Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Priced For Late Stage Use, ImClone Says; McKesson Is Sole Distributor

Executive Summary

The pricing strategy for the oncologic Erbitux reflects the expectation that the biologic will be used primarily in late stage disease, ImClone CEO Daniel Lynch told analysts during a March 15 conference call

You may also be interested in...



Erbitux First-Line Studies Face Enrollment Challenges From Avastin

ImClone is moving Erbitux development forward with an eye on enrollment

Erbitux First-Line Studies Face Enrollment Challenges From Avastin

ImClone is moving Erbitux development forward with an eye on enrollment

Bristol/ImClone Erbitux Launched At $600 Per Vial; $2,400 For Initial Dose

Bristol-Myers Squibb/Imclone's oncologic Erbitux launched Feb. 25 at an average wholesale price of $600 per 100 mg of cetuximab

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel